PHGDH loss promotes hypoxia tolerance through glycolytic reprogramming and enhanced HIF-1 activity.

Eduard Petrosyan, Louise A W Martin, Isabelle Legge, John Walsby-Tickle, Adam C Sedgwick, Mark A Hill, James S O McCullagh, Monica M Olcina, Ester M Hammond

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eduard PetrosyanDepartment of Oncology, The University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-8533-9331

Louise A W MartinDepartment of Oncology, The University of Oxford, Oxford, UK.

Isabelle LeggeChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-5913-4335

John Walsby-TickleChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-1287-9580

Adam C SedgwickDepartment of Chemistry, King's College London, London, UK.

Mark A HillDepartment of Oncology, The University of Oxford, Oxford, UK.

James S O McCullaghChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK.

Monica M OlcinaDepartment of Oncology, The University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-9580-2169

Ester M HammondDepartment of Oncology, The University of Oxford, Oxford, UK. ester.hammond@oncology.ox.ac.uk.ORCID http://orcid.org/0000-0002-2335-3146

Funding

RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/S019901/1

6 · The paper itself

Abstract

Radiotherapy is widely used in the treatment of lung cancer; a number of intrinsic and extrinsic mechanisms of resistance exist, including hypoxia. Targeting metabolic pathways that support redox homeostasis has been proposed as a strategy to enhance radiosensitivity. The serine synthesis pathway enzyme, phosphoglycerate dehydrogenase (PHGDH), has been implicated in resistance to several anticancer therapies; however, its role in radiotherapy response is poorly defined. We show that PHGDH expression positively correlates with established hypoxia gene expression signatures in lung adenocarcinoma and squamous cell carcinoma patient datasets and is induced under hypoxia (<0.1% O

Identifiers

PMID42270601

DOI10.1038/s41420-026-03194-9

PMCPMC13478179

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.